[HTML][HTML] Central serous chorioretinopathy: towards an evidence-based treatment guideline
TJ Van Rijssen, EH Van Dijk, S Yzer… - Progress in retinal and …, 2019 - Elsevier
Central serous chorioretinopathy (CSC) is a common cause of central vision loss, primarily
affecting men 20–60 years of age. To date, no consensus has been reached regarding the …
affecting men 20–60 years of age. To date, no consensus has been reached regarding the …
Central serous chorioretinopathy: update on pathophysiology and treatment
B Nicholson, J Noble, F Forooghian, C Meyerle - Survey of ophthalmology, 2013 - Elsevier
Recent technological advances—new pathophysiological insights, new imaging techniques
for diagnosis and management, and new treatments—have led to an improved …
for diagnosis and management, and new treatments—have led to an improved …
Imaging and photodynamic therapy: mechanisms, monitoring, and optimization
The purpose of this review is to present the current state of the role of imaging in
photodynamic therapy (PDT). For the reader to fully appreciate the context of the discussions …
photodynamic therapy (PDT). For the reader to fully appreciate the context of the discussions …
Central serous chorioretinopathy
M Wang, IC Munch, PW Hasler, C Prünte… - Acta …, 2008 - Wiley Online Library
Central serous chorioretinopathy (CSC) is a disease of the retina characterized by serous
detachment of the neurosensory retina secondary to one or more focal lesions of the retinal …
detachment of the neurosensory retina secondary to one or more focal lesions of the retinal …
Central serous chorioretinopathy: an update on pathogenesis and treatment
M Gemenetzi, G De Salvo, AJ Lotery - Eye, 2010 - nature.com
Central serous chorioretinopathy (CSC) is a chorioretinal disease, incompletely understood
with systemic associations, a multifactorial aetiology, and a complex pathogenesis …
with systemic associations, a multifactorial aetiology, and a complex pathogenesis …
Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial
OBJECTIVE: To evaluate the efficacy of photodynamic therapy (PDT) with half-dose
verteporfin for treating acute central serous chorioretinopathy (CSC). DESIGN: Prospective …
verteporfin for treating acute central serous chorioretinopathy (CSC). DESIGN: Prospective …
Central serous chorioretinopathy
R Liegl, MW Ulbig - Ophthalmologica, 2014 - karger.com
The pathogenesis of central serous chorioretinopathy (CSC) is still not fully understood. The
involvement of corticosteroids is undisputed, although their exact role has not been clarified; …
involvement of corticosteroids is undisputed, although their exact role has not been clarified; …
Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study
Purpose: To evaluate the efficacy of a safety enhanced photodynamic therapy (PDT)
protocol with half-dose verteporfin for treating chronic central serous chorioretinopathy …
protocol with half-dose verteporfin for treating chronic central serous chorioretinopathy …
Interventions for central serous chorioretinopathy: a network meta‐analysis
M Salehi, AS Wenick, HA Law… - Cochrane Database …, 2015 - cochranelibrary.com
Background Central serous chorioretinopathy (CSC) is characterized by serous detachment
of the neural retina with dysfunction of the choroid and retinal pigment epithelium (RPE). The …
of the neural retina with dysfunction of the choroid and retinal pigment epithelium (RPE). The …
Review and update of central serous chorioretinopathy
A Ross, AH Ross, Q Mohamed - Current opinion in ophthalmology, 2011 - journals.lww.com
Review and update of central serous chorioretinopathy : Current Opinion in Ophthalmology
Review and update of central serous chorioretinopathy : Current Opinion in Ophthalmology Log …
Review and update of central serous chorioretinopathy : Current Opinion in Ophthalmology Log …